Thursday, June 19, 2025 6/19/2025

The state of energy in the right ventricle of patients with pulmonary arterial hypertension

Award Number: R01HL153724
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/15/2022
PERIOD OF PERFORMANCE END DATE: 12/31/2026

Group Awards By:

View Award Description

The state of energy in the right ventricle of patients with pulmonary arterial hypertension - PROJECT SUMMARY/ABSTRACT Pulmonary arterial hypertension (PAH) is a progressive cardiopulmonary disease with a high mortality rate. In most cases, PAH-induced chronic pressure overload leads to right ventricle (RV) failure. Right heart catheterization (RHC) is currently the gold standard test for PAH diagnosis and follow-up. Furthermore, repeated RHC should be considered in patients who experience unexplained clinical deterioration during their clinical course or for periodic follow-up over time. Yet many centers across the world do not routinely perform RHC during follow-up, for a variety of potential reasons, including its invasive nature, cost, or availability. We have recently developed 3D echocardiographic particle image velocimetry (Echo-PIV), which allows high- temporal volumetric assessment of RV hemodynamics. In combination with standard 3D speckle tracking, 3D Echo-PIV enables a comprehensive assessment of hemodynamics and energy state (ventricular kinetic energy/work and viscous energy dissipation) in the RV. The RV energy state reflects the structural and functional changes in the RV that may occur due to PAH. Thus, it can be used as a load-independent measure to assess RV function and monitor disease progression/regression in PAH patients. The project's global hypothesis is that in PAH patients' follow-up, changes in the RV energy state: (1) reflect changes in RHC-derived pulmonary arterial pressures, and (2) are associated with changes in patients' clinical status such that it can be used to monitor disease progression and regression. Given that in more advanced disease, RV dysfunction is present, we will gather a prospective, ethnically diverse cohort of 210 subjects at Cedars-Sinai Medical Center: 70 PAH patients with normal RV function, 70 PAH patients with RV dysfunction, and 70 healthy control subjects. The following Specific Aims will be accomplished: SPECIFIC AIM 1: Investigate the accuracy of 3D Echo-PIV in characterizing 4D flow hemodynamics in the RV using 4D Flow CMR as a reference standard and assess test/retest reproducibility of 3D Echo-PIV in PAH. SPECIFIC AIM 2: Determine the relationship between the noninvasively derived RV energy state and RHC- derived parameters in following up PAH patients and test whether changes in the RV energy state reflect changes in the RHC-derived pulmonary arterial pressures in PAH patients with and without RV dysfunction. SPECIFIC AIM 3: Investigate the feasibility of noninvasive imaging-derived RV energy state for monitoring disease progression/regression in PAH patients. The success of the proposed studies will establish 3D Echo-PIV as a tool for assessment of PAH patients and will: (1) determine the relationship between noninvasive RV imaging and invasive RHC-based hemodynamics, (2) establish whether changes in noninvasive RV energy state reflect changes in the RHC-derived parameters in PAH patients, and (3) facilitate monitoring of disease progression/regression by noninvasive RV energy state in lieu of invasive RHC (current clinical gold standard).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $561,825 )
2025	2025	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Lung Diseases Research	002	4	3/12/2025	NON-COMPETING CONTINUATION	$0
2025	2025	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Lung Diseases Research	001	4	12/19/2024	NON-COMPETING CONTINUATION	$561,825
2025	2023	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Lung Diseases Research	000	2	11/23/2024	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $561,825

Issue Date FY: 2024 ( Subtotal = $611,765 )
2024	2024	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Lung Diseases Research	004	3	6/8/2024	NON-COMPETING CONTINUATION	$0
2024	2024	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Lung Diseases Research	003	3	6/6/2024	NON-COMPETING CONTINUATION	$611,765
2024	2023	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Lung Diseases Research	002	2	6/5/2024	NON-COMPETING CONTINUATION	$0
2024	2023	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Lung Diseases Research	000	2	3/1/2024	SUPPLEMENT FOR EXPANSION	$0
2024	2022	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Lung Diseases Research	001	1	5/23/2024	NEW	$0
														Subtotal = $611,765

Issue Date FY: 2023 ( Subtotal = $1,290,560 )
2023	2023	UNIVERSITY OF CALIFORNIA, IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Lung Diseases Research	001	2	3/15/2023	NON-COMPETING CONTINUATION	$64,529
2023	2023	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Lung Diseases Research	002	2	9/12/2023	SUPPLEMENT FOR EXPANSION	$645,279
2023	2023	UNIVERSITY OF CALIFORNIA, IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Lung Diseases Research	000	2	1/6/2023	NON-COMPETING CONTINUATION	$580,752
														Subtotal = $1,290,560

Issue Date FY: 2022 ( Subtotal = $671,932 )
2022	2022	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Lung Diseases Research	000	1	1/15/2022	NEW	$671,932
														Subtotal = $671,932

Grand Total All Awards = $3,136,082

Top

	
		OSZAR »

All Categories

About

Search

Reports

Data Submission

Award Information

The state of energy in the right ventricle of patients with pulmonary arterial hypertension

Award Number: R01HL153724

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/15/2022

PERIOD OF PERFORMANCE END DATE: 12/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer